# Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a

> **NCT02646371** · PHASE2 · COMPLETED · sponsor: **LimmaTech Biologics AG** · enrollment: 67 (actual)

## Conditions studied

- Shigellosis

## Interventions

- **BIOLOGICAL:** Flexyn2a
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02646371
- **Lead sponsor:** LimmaTech Biologics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-09
- **Final completion:** 2017-07
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2021-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02646371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02646371, "Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02646371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*